Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen
Executive Summary
The latest HIV drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow
Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.
ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings
The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.
Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?